Stockreport

GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk

GSK plc American Depositary Shares (Each representing two Ordinary Shares)  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this populationAdults aged 50 and above wit [Read more]